Literatur
-
1
Beer J H.
Prevention of venous thromboembolism in internal medicine patients.
Ther Umsch.
1992;
49
825-832
-
2
Bergqvist D, Agnelli G, Cohen A T, Eldor A, Nilsson P E, Moigne-Amrani A L, Dietrich-Neto F. for the Enoxacan II investigators .
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
N Engl J Med.
2002;
346
975-980
-
3
Bernstein C N, Blanchard J F, Houston D S, Wajda A.
The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study.
Thromb Haemost.
2001;
85
430-434
-
4 Cohen A T. Fondaparinux versus placebo for venous thromboembolism in medical patients. ISTH Abstract 2003
-
5
Geerts W H, Pineo G F, Heit J A. et al .
Prevention of venous thromboembolism.
Chest.
2004;
126
338S-400S
-
6
Haas S.
At-Home-Studie: Konsequente Thromboseprophylaxe auch bei bettlägerigen Hausarztpatienten.
Hämostaseologie.
2004;
24
91-93
-
7
Harenberg J, Roebruck P, Heene D L.
Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group.
Haemostasis.
1996;
26
127-139
-
8
Havig O.
Deep vein thrombosis and pulmonary embolism: An autopsy study with multiple regression analysis of possible risk factors.
Acta Chirurg Scand.
1977;
478
1-120
-
9
Hills N H, Pflug J J, Jeyasingh K, Boardman L, Calnan J S.
Prevention of deep vein thrombosis by intermittent pneumatic compression of calf.
Br Med J.
1972;
1
131-135
-
10
Kakkar A K.
Thrombosis and cancer.
Hematol J.
2004;
5
S20-S23
(Suppl 3)
-
11
Kleber F X, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach C W. THE-PRINCE Study Group .
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
Am Heart J.
2003;
145
614-621
-
12
Lechler E, Schramm W, Flosbach C W.
The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heaprin (enoxaparin). The Prime Study Group.
Haemostasis.
1996;
26
49-56
(Suppl 2)
-
13
Leizorovicz A, Cohen A T, Turpie A G. et al .
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Circulation.
2004;
110
874-879
-
14
Maurer B J, Wray R, Shillingford J P.
Frequency of venous thrombosis after myocardial infarction.
Lancet.
1971;
2
1385-1387
-
15
Miller R R, Lies J E, Carretta R F. et al .
Prevention of lower extremity venous thrombosis by early mobilization. Confirmation in patients with acute myocardial infarction by 125I-fibrinogen uptake and venography.
Ann Intern Med.
1976;
84
700-703
-
16
Mismetti P, Laporte-Simitsidis S, Tardy B. et al .
Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.
Thromb Haemost.
2000;
83
14-19
-
17
Murray T S, Lorimer A R, Cox F C, Lawrie T DV.
Leg-vein thrombosis following myocardial infarction.
Lancet.
1970;
2
792-793ii
-
18
Negus D, Pinto D J, Le Quesne L P, Brown N, Chapman M.
125-I-labelled fibrinogen in the diagnosis of deep-vein thrombosis and its correlation with phlebography.
Br J Surg.
1968;
55
835-839
-
19
Nicolaides A N, Kakkar V V, Field E S, Fish P.
Optimal electrical stimulus for prevention of deep vein thrombosis.
Br Med J.
1972;
3
756-758
-
20
Nicolaides A N, Breddin H K, Fareed J. et al .
Cardiovascular Disease Educational and Research Trust and the International Union of Angiology. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence.
Int Angiol.
2001;
20
1-37
-
21
Planes A, Vochelle N, Darmon J Y. et al .
Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of Enoxaparin versus placebo.
Lancet.
1996;
348
224-228
-
22
Riedler G F.
Thromboseprophylaxe in der Inneren Medizin.
Therapeutische Umschau.
1977;
34
363-367
-
23
Samama M M, Cohen A T, Darmon J Y. et al .
A comparison or enoxaparin with placebo for the prevention of venous thrombembolism in acutely ill medical patients.
N Engl J Med.
1999;
341
793-800
-
24
Warkentin T E, Greinacher A.
Heparin-induced thrombocytopenia: Recognition, treatment and prevention.
Chest.
2004;
126
311S-337S
Priv.-Doz. Dr. med. Knut Kröger
Klinik und Poliklinik für Angiologie, Universitätsklinik Essen
Hufelandstraße 55
45122 Essen
Phone: 0201/7232530
Fax: 0201/7235967
Email: knut.kroeger@uni-essen.de
